Oral solid compritol 888 ATO nanosuspension of simvastatin: Optimization and biodistribution studies

Drug Development and Industrial Pharmacy

Volumn 37, Issue 5, 2011, Pages 526-537

  Shah, Mayank ^a   Chuttani, Krishna ^b   Mishra, A K ^b   Pathak, Kamla ^a  

^a Rajiv Academy for Pharmacy ^*  (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

bioavailability; biodistribution; compritol 888 ATO; response surface plots; Simvastatin; solid lipid nanoparticles

Indexed keywords

ACETONE; GLYCEROL BEHENATE; NANOPARTICLE; POLOXAMER; SIMVASTATIN; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG RELEASE; FACTORIAL ANALYSIS; ISOTOPE LABELING; LIVER METABOLISM; MOUSE; NONHUMAN; PARTICLE SIZE; PROCESS OPTIMIZATION; RESPONSE SURFACE METHOD;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; FATTY ACIDS; ISOTOPE LABELING; MICE; NANOPARTICLES; PARTICLE SIZE; SIMVASTATIN; TISSUE DISTRIBUTION;

EID: 79953785891     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2010.527983     Document Type: Article

References (27)

1. Ali H, Shirode AB, Sylvester PW, Nazzal S. (2010). Preparation, characterization, and anticancer effects of simvastatin-tocotrienol lipid nanoparticles. Int J Pharm, 389, 223-231.
2. Almeida AJ, Runge S, Muller RH. (1997). Peptide-loaded solid lipid nanoparticles: influence of production parameters. Int J Pharm, 149, 255-265. (Pubitemid 27193412)
3. Babbar AK, Kashyap R, Chauhan UP. (1991). A convenient method for the preparation of 99mTc-labelled pentavalent DMSA and its evaluation as a tumor imaging agent. J Nucl Bio Med, 35, 100-104.
4. Bhavsar MD, Tiwari SB, Amiji MM. (2006). Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release, 110, 422-430. (Pubitemid 41827496)
5. Bolton S, Bon C. (2004). Pharmaceutical Statistics: Practical and Clinical Application, 4th ed. New York: Marcel Dekker.
6. Marcel Dekker. Derakhshandeh K, Erfan M, Dadashzadeh S. (2007). Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics. Eur J Pharm Biopharm, 66, 34-41. (Pubitemid 46412968)
7. Freitas C, Muller RH. (1998). Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle dispersions. Int J Pharm, 168, 221-229. (Pubitemid 28349963)
8. Goodman, and Gilman's(2006). The Pharmacological basis of Therapeutics, 10th ed. Hardman JG, Limbird LE, Eds. New York: McGraw-Hill.
9. Leroux JC, Allemann E, Doelker E, Gurny R. (1994). New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm, 41, 14-18.
10. Maaßen S, Schwarz C, Mehnert W, Lucks JS, Yunis-Specht F, Muller BW, Muller RH. (1993). Comparison of cytotoxicity between polyester nanoparticles and solid lipid nanoparticles. Proc Int Symp Control Rel Bioact Mater, 20, 490-491. (Pubitemid 23269705)
11. Manjunath K, Reddy JS, Venkateswarlu V. (2005). Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol, 27, 127-144.
12. Margulis-Goshen K, Magdassi S. (2009). Formation of simvastatin nanoparticles from microemulsion. Nanomedicine, 5, 274-281.
13. Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev, 47, 165-196. (Pubitemid 32324113)
14. Mishra P, Babbar A, Chauhan UP. (1991). A rapid instant thin layer chromatographic procedure for determining radiochemical purity of 99Tcm-IDA agents. Nucl Med Commun, 12, 467-469.
15. Mukherjee S, Ray S, Thakur RS. (2007). The current status of solid lipid nanoparticles. Pharmbit, XV, 53-60.
16. Muller RH, Maaßen S, Weyhers H, Specht F, Lucks JS. (1996). Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles. Int J Pharm, 138, 85-94. (Pubitemid 26241925)
17. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50, 161-177. (Pubitemid 30326695)
18. Nastruzzi C. (2005). Lipospheres in Drug Targets and Delivery. New York: CRC Press.
19. Nezasa K, Higaki K, Matsumura T, Inazawa K, Hasegawa H, Nakano M, Koike M. (2002). Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab Dispos, 30, 1158-1163. (Pubitemid 35265820)
20. Nishioka Y, Yoshino H. (2001). Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev, 47, 55-64. (Pubitemid 32209232)
21. Schubert MA, Müller-Goymann CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm, 55, 125-131. (Pubitemid 36120504)
22. Shah M, Pathak K. (2010). Development and statistical optimization of solid lipid nanoparticles of simvastatin by using 23 full factorial design. AAPS Pharm Sci Tech, [online 23 March 2010%%Ea.
23. Suresh G, Manjunath K, Venkateswarlu V, Satyanarayana V. (2007). Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS PharmSciTech, 8, 24.
24. Theobald AE. (1990). Textbook of Radiopharmacy: Theory and Practice. Sampson CB, Ed. Gordon and Breach New York.
25. Vanderbast F, Sereno A, Bauduer P. (2007). Oral pharmaceutical composition containing a statin derivative. US Patent 4667088.
26. Yang S, Zhu J, Lu Y, Liang B, Yang C. (1999). Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res, 16, 751-757. (Pubitemid 29227107)
27. Zhang D, Tan T, Gao L. (2003). Preparation of oridonin-loaded solid lipid nanoparticles and studies on them in vitro and in vivo. Nanotechnology, 17, 5821-5828.